170 related articles for article (PubMed ID: 16337744)
21. COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
Yamanaka Y; Shiraki K; Inoue T; Miyashita K; Fuke H; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
Int J Mol Med; 2006 Jul; 18(1):41-7. PubMed ID: 16786154
[TBL] [Abstract][Full Text] [Related]
22. Targeting fibroblast growth factor receptor signaling in hepatocellular carcinoma.
Cheng AL; Shen YC; Zhu AX
Oncology; 2011; 81(5-6):372-80. PubMed ID: 22269894
[TBL] [Abstract][Full Text] [Related]
23. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma.
Pang R; Poon RT
Cancer Lett; 2006 Oct; 242(2):151-67. PubMed ID: 16564617
[TBL] [Abstract][Full Text] [Related]
24. Thrombin-mediated hepatocellular carcinoma cell migration: cooperative action via proteinase-activated receptors 1 and 4.
Kaufmann R; Rahn S; Pollrich K; Hertel J; Dittmar Y; Hommann M; Henklein P; Biskup C; Westermann M; Hollenberg MD; Settmacher U
J Cell Physiol; 2007 Jun; 211(3):699-707. PubMed ID: 17323377
[TBL] [Abstract][Full Text] [Related]
25. Cyclooxygenase-2 inhibitor and interferon-beta synergistically induce apoptosis in human hepatoma cells in vitro and in vivo.
Nakamoto N; Higuchi H; Kanamori H; Kurita S; Tada S; Takaishi H; Toda K; Yamada T; Kumagai N; Saito H; Hibi T
Int J Oncol; 2006 Sep; 29(3):625-35. PubMed ID: 16865278
[TBL] [Abstract][Full Text] [Related]
26. Prostaglandin E2 receptors and COX enzymes in human hepatocellular carcinoma: role in the regulation of cell growth.
Cusimano A; Foderà D; Lampiasi N; Azzolina A; Notarbartolo M; Giannitrapani L; D'Alessandro N; Montalto G; Cervello M
Ann N Y Acad Sci; 2009 Feb; 1155():300-8. PubMed ID: 19250221
[TBL] [Abstract][Full Text] [Related]
27. Effect of simultaneous inhibition of epidermal growth factor receptor and cyclooxygenase-2 in HER-2/neu-positive breast cancer.
Lanza-Jacoby S; Burd R; Rosato FE; McGuire K; Little J; Nougbilly N; Miller S
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6161-9. PubMed ID: 17062693
[TBL] [Abstract][Full Text] [Related]
28. [Significance of cyclooxygenase-2 as a chemotherapeutic target in hepatocellular carcinoma].
Kern MA; Schirmacher P; Breinig M
Verh Dtsch Ges Pathol; 2007; 91():257-68. PubMed ID: 18314623
[TBL] [Abstract][Full Text] [Related]
29. Cyclooxygenases in hepatocellular carcinoma.
Cervello M; Montalto G
World J Gastroenterol; 2006 Aug; 12(32):5113-21. PubMed ID: 16937518
[TBL] [Abstract][Full Text] [Related]
30. M. bovis BCG induced expression of COX-2 involves nitric oxide-dependent and -independent signaling pathways.
Bansal K; Narayana Y; Patil SA; Balaji KN
J Leukoc Biol; 2009 May; 85(5):804-16. PubMed ID: 19228814
[TBL] [Abstract][Full Text] [Related]
31. Influence of simultaneous inhibition of cyclooxygenase-2 and inducible nitric oxide synthase in experimental colitis in rats.
Dudhgaonkar SP; Tandan SK; Kumar D; Raviprakash V; Kataria M
Inflammopharmacology; 2007 Oct; 15(5):188-95. PubMed ID: 17943250
[TBL] [Abstract][Full Text] [Related]
32. Hepatocyte growth factor and inducible nitric oxide synthase are involved in multidrug resistance-induced angiogenesis in hepatocellular carcinoma cell lines.
Lasagna N; Fantappiè O; Solazzo M; Morbidelli L; Marchetti S; Cipriani G; Ziche M; Mazzanti R
Cancer Res; 2006 Mar; 66(5):2673-82. PubMed ID: 16510587
[TBL] [Abstract][Full Text] [Related]
33. Advances in prevention and diagnosis of hepatocellular carcinoma.
Spangenberg HC; Thimme R; Blum HE
Expert Rev Gastroenterol Hepatol; 2008 Jun; 2(3):425-33. PubMed ID: 19072390
[TBL] [Abstract][Full Text] [Related]
34. Induction of angiopoietin-2 gene expression by COX-2: a novel role for COX-2 inhibitors during hepatocarcinogenesis.
Tanaka S; Wands JR; Arii S
J Hepatol; 2006 Jan; 44(1):233-5. PubMed ID: 16290311
[No Abstract] [Full Text] [Related]
35. Potential involvement of the cyclooxygenase-2 pathway in hepatocellular carcinoma-associated angiogenesis.
Zhao QT; Yue SQ; Cui Z; Wang Q; Cui X; Zhai HH; Zhang LH; Dou KF
Life Sci; 2007 Jan; 80(5):484-92. PubMed ID: 17097688
[TBL] [Abstract][Full Text] [Related]
36. Cross-talk between peroxisome proliferator-activated receptor delta and cytosolic phospholipase A(2)alpha/cyclooxygenase-2/prostaglandin E(2) signaling pathways in human hepatocellular carcinoma cells.
Xu L; Han C; Lim K; Wu T
Cancer Res; 2006 Dec; 66(24):11859-68. PubMed ID: 17178883
[TBL] [Abstract][Full Text] [Related]
37. Toward the discovery of new biomarkers of hepatocellular carcinoma by proteomics.
Santamaría E; Muñoz J; Fernández-Irigoyen J; Prìeto J; Corrales FJ
Liver Int; 2007 Mar; 27(2):163-73. PubMed ID: 17311610
[TBL] [Abstract][Full Text] [Related]
38. Functional role of peroxisome-proliferator-activated receptor γ in hepatocellular carcinoma.
Wu CW; Farrell GC; Yu J
J Gastroenterol Hepatol; 2012 Nov; 27(11):1665-9. PubMed ID: 22742931
[TBL] [Abstract][Full Text] [Related]
39. Molecular targeted therapy for hepatocellular carcinoma: bench to bedside.
Kudo M
Dig Dis; 2011; 29(3):273-7. PubMed ID: 21829017
[TBL] [Abstract][Full Text] [Related]
40. New strategy of antiangiogenic therapy for hepatocellular carcinoma.
Wu XZ
Neoplasma; 2008; 55(6):472-81. PubMed ID: 18999874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
